| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bf82b2c04febd9f5fc6ead8595272b9a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575 |
| filingDate |
2002-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_230b08160c80fe23de9be8b04e01cc8e |
| publicationDate |
2004-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1390035-A1 |
| titleOfInvention |
Method for treating ocular hypertension and glaucoma |
| abstract |
A method for treating ocular hypertension and glaucoma, which comprises an administration of eye drops comprising a 15-keto-prostaglandin compound as an active ingredient to a subject in need of such treatment in a single administration volume of at least 20 mu muL/eye is disclosed. According to the present method, the intraocular pressure reducing effect of the compound is surprisingly augmented. |
| priorityDate |
2001-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |